APA (7th ed.) Citation

F, L., J, W., J, Q., G, W., L, X., & Z, W. (2026). Sphingolipid-associated signature unveils TIMP1-driven temozolomide resistance and guides stratified therapy in glioblastoma. Frontiers in immunology, 17, 1753274. https://doi.org/10.3389/fimmu.2026.1753274

Chicago Style (17th ed.) Citation

F, Lyu, Wu J, Qi J, Wang G, Xie L, and Wang Z. "Sphingolipid-associated Signature Unveils TIMP1-driven Temozolomide Resistance and Guides Stratified Therapy in Glioblastoma." Frontiers in Immunology 17 (2026): 1753274. https://doi.org/10.3389/fimmu.2026.1753274.

MLA (9th ed.) Citation

F, Lyu, et al. "Sphingolipid-associated Signature Unveils TIMP1-driven Temozolomide Resistance and Guides Stratified Therapy in Glioblastoma." Frontiers in Immunology, vol. 17, 2026, p. 1753274, https://doi.org/10.3389/fimmu.2026.1753274.